Welcome to our dedicated page for Immuneering SEC filings (Ticker: IMRX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page provides access to Immuneering Corporation’s (Nasdaq: IMRX) SEC filings, offering a detailed view of how the clinical-stage oncology company reports its operations, financings, and key developments. Immuneering’s Class A common stock is listed on The Nasdaq Global Market, and its Exchange Act reports and current reports on Form 8‑K document material events and corporate actions related to its Deep Cyclic Inhibitor programs.
Through Forms 10‑K and 10‑Q, investors can review Immuneering’s descriptions of its business, risk factors, research and development activities, and financial condition. Current reports on Form 8‑K capture specific events such as underwritten public offerings of Class A common stock, private placements with institutional investors, entry into material definitive agreements, and announcements of clinical data from the atebimetinib program. For example, recent 8‑K filings describe the company’s securities purchase agreement with a Sanofi subsidiary, the terms of a public offering, and updated interim data from a Phase 2a trial of atebimetinib plus modified gemcitabine/nab-paclitaxel in first-line pancreatic cancer.
On Stock Titan, these filings are updated in near real time as they appear on EDGAR and are paired with AI-powered summaries that highlight the most important points. Long, technical documents are distilled to explain how financings affect Immuneering’s cash runway, what new clinical or regulatory milestones are disclosed, and how agreements such as equity distribution arrangements or clinical collaborations fit into the company’s strategy. Users can also track sections that discuss patent protection for atebimetinib, including the U.S. composition of matter patent, and references to planned pivotal Phase 3 trials and combination studies in non-small cell lung cancer.
In addition, this page allows investors to quickly locate any insider transaction reports on Form 4, proxy statements on Schedule 14A, and registration statements or prospectus supplements related to securities offerings, when available. By combining structured access to Immuneering’s filings with AI explanations, the platform helps readers understand how regulatory disclosures relate to the company’s Deep Cyclic Inhibitor pipeline, clinical development plans, and capital structure without having to parse every page manually.
Immuneering Corporation (IMRX) – Form 4 insider transaction: On 06/18/2025, President, CEO, Director and 10% owner Benjamin J. Zeskind bought 21,000 shares of Class A common stock on the open market at a weighted-average price of $2.3878 per share (trades ranged $2.31-$2.44). The filing was signed on 06/20/2025.
Following the purchase, Zeskind directly owns 2,302,852 shares. In addition, an indirect holding of 894,927 shares is held by the Benjamin J. Zeskind 2020 Family Trust, for which his spouse serves as sole trustee. The transaction was coded “P” (open-market purchase), indicating an increase in ownership. The form does not reference any Rule 10b5-1 trading plan.
The purchase represents roughly 0.9% of Zeskind’s direct stake and signals continued insider support, but the absolute amount (≈$50 k) is modest relative to his existing 3.2 million-share economic interest.